Tempus AI CEO Sells $7.7M After Material Agreement
NEW YORK, June 14 —
On May 13, 2026, Tempus AI filed an 8-K disclosing a new Material Definitive Agreement, a filing that named no counterparty and described no deal terms. Six days later, five C-suite executives sold shares in simultaneous open-market transactions. Eight days after that, CEO Eric Lefkofsky returned for another $7.76 million in personal sales. The combined insider selling over the trailing 90 days totals $10.29 million against zero purchases, per Form 4 filings, arriving just as the company posts its strongest operating metrics.
- Trailing twelve-month revenue of $1.36 billion, up 36.1% year over year
- Three consecutive EPS beats: most recent quarter, -$0.04 actual versus -$0.05 estimated
- $10.29 million in open-market insider sales against $0 in purchases over the trailing 90 days, per Form 4 filings
The Agreement Nobody Named
The May 13 8-K filing disclosed that Tempus entered a Material Definitive Agreement under Item 1.01, the SEC category for contracts significant enough to require immediate disclosure. The filing names no counterparty and describes no terms. That omission is permissible under certain conditions, but it leaves investors with a factual gap at precisely the moment executive selling accelerated.
Five Executives, One Day
On May 19, five Tempus AI executives sold shares simultaneously at $44.07 per share. Lefkofsky sold 22,335 shares for $984,303; CFO James Rogers sold 10,853 shares for $478,292; Chief Legal Officer Andrew Polovin sold 8,703 shares for $383,541; CEO of Data Ryan Fukushima sold 13,550 shares for $597,149; and CEO of Diagnostics Thomas Schoenherr sold 1,580 shares for $69,631. Five executives, five different roles, one price, one day. Eight days later, Lefkofsky returned to sell 166,250 additional shares across four transactions at $46.17 and $46.89 per share, generating another $7.76 million in proceeds.
Beats on Paper, Burns Cash
The selling pattern sits uncomfortably alongside an otherwise constructive operating picture. Tempus has beaten consensus EPS estimates in each of its three most recently reported quarters: -$0.04 actual versus -$0.05 estimated in the most recent period; -$0.11 versus -$0.18 the quarter prior; and -$0.22 versus -$0.25 the quarter before that, per the results disclosed in Tempus's May 5 8-K filing. Revenue of $1.36 billion on a trailing basis represents 36.1% year-over-year growth, and gross margin holds at 63.4%. The complication: trailing free cash flow remains negative at $56 million. A high-margin, fast-growing company burning cash is a story investors have told themselves before; the variable is when the trajectory turns.
The FDA Tailwind
Separate from the insider activity, Tempus has received new FDA clearances for genomics and cardiac AI products. Among them is an AI-powered ECG model that reportedly estimates atrial fibrillation risk approximately one year in advance. Earlier detection gives clinicians more time to intervene, and clearances across both genomics and cardiac AI signal the company is building regulatory credibility across multiple product lines. Whether these clearances translate to incremental revenue in the near term depends on clinical adoption curves that are difficult to model from the outside.
What to Watch
The key open question is the May 13 Material Definitive Agreement: what is it, and with whom? If the deal surfaces in a subsequent filing or earnings call, that context will reframe the insider selling, either as executives locking in gains ahead of a known catalyst or as routine portfolio management running on a pre-set schedule. Separately, whether free cash flow turns positive in coming quarters matters for the multiple the market is willing to assign a still-unprofitable company growing at 36%. The FDA clearances in genomics and cardiac AI provide a potential commercial catalyst; adoption data and any related revenue commentary would be the signal to track.
Run the free Tempus AI, Inc. deep-dive →
Basis Report does not hold positions in securities discussed. This is not investment advice.
Frequently Asked Questions
What is Tempus AI's insider selling activity?
Over the trailing 90 days, Tempus AI insiders sold approximately $10.29 million in shares on the open market against zero purchases, per Form 4 filings. The selling involved five executives in a coordinated May 19, 2026 round and a second set of sales by CEO Eric Lefkofsky alone on May 27.
Did Tempus AI beat earnings estimates?
Tempus AI beat consensus EPS estimates in each of its three most recently reported quarters. The most recent quarter showed actual EPS of -$0.04 against an estimate of -$0.051, continuing a trend of steadily narrowing losses.
What is Tempus AI's revenue growth rate?
Tempus AI's trailing twelve-month revenue stands at $1.36 billion, reflecting year-over-year growth of 36.1%. Gross margin on a trailing basis is 63.4%, though free cash flow remains negative at -$56 million.
Why did the Tempus AI CEO sell stock?
CEO Eric Lefkofsky sold shares on two occasions in May 2026: 22,335 shares at $44.07 on May 19 and 166,250 shares at prices between $46.17 and $46.89 on May 27, for combined proceeds of approximately $8.75 million. The Form 4 filings do not disclose a stated reason for the sales.
What FDA clearances has Tempus AI received?
News reporting indicates Tempus AI has received new FDA clearances for genomics and cardiac AI products. One product reportedly includes an ECG model designed to estimate atrial fibrillation risk approximately one year in advance.